Tags

Type your tag names separated by a space and hit enter

Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial.
Gastroenterology. 2011 Aug; 141(2):536-43.G

Abstract

BACKGROUND & AIMS

Pain is a disabling symptom for patients with chronic pancreatitis (CP) and difficult to treat. Evidence from basic science and human studies indicates that pain processing by the central nervous system is abnormal and resembles that observed in patients with neuropathic pain disorders. We investigated whether agents used to treat patients with neuropathic pain are effective in CP.

METHODS

We conducted a randomized, double-blind, placebo-controlled trial to evaluate the effects of the gabapentoid pregabalin as an adjuvant analgesic. We measured pain relief, health status, quality of life, and tolerability in 64 patients with pain from CP; they were randomly assigned to groups given increasing doses of pregabalin or placebo (control) for 3 consecutive weeks. The primary end point was pain relief, based on a visual analogue scale documented by a pain diary. Secondary end points included Patients' Global Impression of Change (PGIC) score, changes in physical and functional scales, pain character, quality of life, and tolerability.

RESULTS

Pregabalin, compared with placebo, caused more effective pain relief after 3 weeks of treatment (36% vs 24%; mean difference, 12%; 95% confidence interval, 22%-2%; P = .02). The percentage of patients with much or very much improved health status (PGIC score) at the end of the study was higher in the pregabalin than the control group (44% vs 21%; P = .048). Changes in physical and functional scales, pain character, quality of life, and number of serious adverse events were comparable between groups.

CONCLUSIONS

In a placebo-controlled trial, pregabalin is an effective adjuvant therapy for pain in patients with CP.

Authors+Show Affiliations

Mech-Sense, Department of Gastroenterology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21683078

Citation

Olesen, Søren Schou, et al. "Pregabalin Reduces Pain in Patients With Chronic Pancreatitis in a Randomized, Controlled Trial." Gastroenterology, vol. 141, no. 2, 2011, pp. 536-43.
Olesen SS, Bouwense SA, Wilder-Smith OH, et al. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141(2):536-43.
Olesen, S. S., Bouwense, S. A., Wilder-Smith, O. H., van Goor, H., & Drewes, A. M. (2011). Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology, 141(2), 536-43. https://doi.org/10.1053/j.gastro.2011.04.003
Olesen SS, et al. Pregabalin Reduces Pain in Patients With Chronic Pancreatitis in a Randomized, Controlled Trial. Gastroenterology. 2011;141(2):536-43. PubMed PMID: 21683078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. AU - Olesen,Søren Schou, AU - Bouwense,Stefan A W, AU - Wilder-Smith,Oliver H G, AU - van Goor,Harry, AU - Drewes,Asbjørn Mohr, Y1 - 2011/04/14/ PY - 2011/01/06/received PY - 2011/03/07/revised PY - 2011/04/08/accepted PY - 2011/6/21/entrez PY - 2011/6/21/pubmed PY - 2011/10/14/medline SP - 536 EP - 43 JF - Gastroenterology JO - Gastroenterology VL - 141 IS - 2 N2 - BACKGROUND & AIMS: Pain is a disabling symptom for patients with chronic pancreatitis (CP) and difficult to treat. Evidence from basic science and human studies indicates that pain processing by the central nervous system is abnormal and resembles that observed in patients with neuropathic pain disorders. We investigated whether agents used to treat patients with neuropathic pain are effective in CP. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to evaluate the effects of the gabapentoid pregabalin as an adjuvant analgesic. We measured pain relief, health status, quality of life, and tolerability in 64 patients with pain from CP; they were randomly assigned to groups given increasing doses of pregabalin or placebo (control) for 3 consecutive weeks. The primary end point was pain relief, based on a visual analogue scale documented by a pain diary. Secondary end points included Patients' Global Impression of Change (PGIC) score, changes in physical and functional scales, pain character, quality of life, and tolerability. RESULTS: Pregabalin, compared with placebo, caused more effective pain relief after 3 weeks of treatment (36% vs 24%; mean difference, 12%; 95% confidence interval, 22%-2%; P = .02). The percentage of patients with much or very much improved health status (PGIC score) at the end of the study was higher in the pregabalin than the control group (44% vs 21%; P = .048). Changes in physical and functional scales, pain character, quality of life, and number of serious adverse events were comparable between groups. CONCLUSIONS: In a placebo-controlled trial, pregabalin is an effective adjuvant therapy for pain in patients with CP. SN - 1528-0012 UR - https://www.unboundmedicine.com/medline/citation/21683078/Pregabalin_reduces_pain_in_patients_with_chronic_pancreatitis_in_a_randomized_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(11)00474-4 DB - PRIME DP - Unbound Medicine ER -